Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 212

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 212
---
 to continue to hold units or separate their units into the component securities. Holders will need to have their brokers contact our transfer agent in order to separate the units into ordinary shares and rights. Additionally, the units will automatically separate into their component parts and will not be traded after completion of our initial business combination. In no event will the ordinary shares and rights be traded separately until we have filed with the SEC a Current Report on Form 8 -Kwhich includes an audited balance sheet of the company reflecting our receipt of the gross proceeds at the closing of this offering. We will file the Current Report on Form 8 -Kpromptly after the closing of this offering which will include this audited balance sheet. If the underwriters’ over -allotmentoption is exercised following the initial filing of such Current Report on Form 8 -K, a second or amended Current Report on Form 8 -Kwill be filed to provide updated financial information to reflect the exercise of the underwriters’ over -allotmentoption. ORDINARY SHARES Upon the closing of this offering 29,171,429 ordinary shares will be issued and outstanding (assuming no exercise of the underwriters’ over -allotmentoption and the corresponding surrender and forfeiture of 1,285,714 founder shares by our initial shareholders), including: •8,571,429 ordinary shares held by our initial shareholders; •20,000,000 ordinary shares underlying the units being offered in this offering; •400,000 ordinary shares underlying the private units; and •200,000 ordinary shares held by the underwriters. Holders of record of ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders and vote together as a single class, except as required by law. Unless specified in our amended and restated memorandum and articles of association, or as required by applicable law or stock exchange rules, the affirmative vote of holders of a majority of the outstanding ordinary shares that are voted is required to approve any such matter voted on by our shareholders. Our board of directors will be divided into three classes, each of which will generally serve for a term of three years with only one class of directors being elected in each year. There is no cumulative voting with respect to the appointment of directors. Our shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds legally available therefor. 135 Because our amended and restated memorandum and articles of association will authorize the issuance of up to 220